Pharmacy Channel Adoption And Bihormonal Pipeline Will Drive Long Term Diabetes Care Impact

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

14 Dec 25

Updated

24 Jul 26

Views

Not Invested

Shared on 24 Jul 26

Fair value Decreased 37%

BBNX: I Expect Real World Data Transparency Will Drive Future Confidence

Beta Bionics puts more of its iLet performance out in the open with a new real‑world results dashboard, aiming to build trust with clinicians and patients as it pushes for wider use. At the same time, a string of recalls and a lower market view of what the business is worth raise the stakes on clean execution and the planned Mint launch.

2 views

Fair Value vs Share Price

US$19.8

vs US$17.5711.3% undervalued

35.8%

Revenue growth

11.8%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Beta Bionics

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with low risk.

Market capUS$813.4m

PB3.1x

Estimated Growth24.5%

Dividend YieldN/A

Full analysis

CEO & management

Sean Saint

CEO

3.8yrs

CEO Tenure

A commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.